| |
Group |
Company |
| R'000 |
2024 |
2023 |
2024 |
2023 |
| Cash-settled share-based payment liability |
|
|
| |
| Balance at the beginning of the year |
21 298 |
20 312 |
21 298 |
20 312 |
| Share-based payment expense* |
14 624 |
11 115 |
14 624 |
11 115 |
| Share grants vested and paid |
(15 283) |
(10 129) |
(15 283) |
(10 129) |
| Balance at the end of the year |
20 639 |
21 298 |
20 639 |
21 298 |
| Non-current liability |
7 254 |
10 040 |
7 254 |
10 040 |
| Current liability |
13 385 |
11 258 |
13 385 |
11 258 |
|
| 20 639 |
21 298 |
20 639 |
21 298 |
| * |
The expense is charged to profit and loss R15 million (2023: R11 million). |
Cash-settled grants
Shareholders approved the Share Incentive Scheme (Scheme) on 13 April 2010. Over time, various share grants and options were issued to directors and employees of the Company.
The purpose of the share incentive scheme is to serve as an incentive and reward to employees (including executive
directors) of the Company and its subsidiary for services rendered and to be rendered, aimed at promoting the
continued growth of the Company by giving employees an opportunity to acquire shares in the Company and to
serve as a retention mechanism for employees whose services are regarded by the Company to be crucial to the
future growth and sustainability of the Company's business. The Board grants share options and share grants on
the recommendation of the Remuneration Committee.
0.6 million share grants (2023: 1.1 million) were forfeited due to performance conditions not being met.
The Monte Carlo option pricing model was used to determine the fair value of the share grants.
The vesting of the grants is based solely on performance measured based on two conditions: 50% based on Merafe's total shareholder return (TSR) and 50% based on HEPS growth.
If Merafe's TSR over the three years places it in one of the top four positions, then 50% of the number of performance
shares granted (TSR Portion) will vest in equal proportions on the 3rd, 4th and 5th anniversaries of their grant.
If Merafe's TSR over the three years places it in 6th position, then one-third of the TSR Portion will vest in equal
proportions on the 3rd, 4th and 5th anniversaries of their grant. If Merafe's performance over the three years lies
between any of the above points, then a prorated number of the TSR Portion will vest in equal proportions on the
3rd, 4th and 5th anniversaries of their grant. No share grants will vest for positions seven and less.
Vesting of the other 50% of grant shares will be in accordance with the following policy as determined by the Board:
- The performance shares allocated will be subject to performance against the growth in HEPS measure;
- If performance meets or exceeds the target, ie CPI + 2% per annum over the performance period, 100% of shares will vest;
- If performance is at the threshold, ie CPI + 1% per annum over the performance period, 50% of shares subject to this measure will vest;
- For performance below the threshold, 0% of shares subject to this measure will vest; and
- Linear vesting will take place between different performance milestones.
In terms of the rules of the Scheme, the Company retains the discretion and the right to settle awards through the
issue of new shares or in cash. As at 31 December 2024, the Company may still issue 97 885 481 Merafe shares to
settle any awards contemplated under the Scheme upon vesting.
Accordingly, the Company may still issue up to the maximum number of shares contemplated under the Scheme to settle any awards.
The following assumptions were used in the valuation model:
|
| 2024
2020 – 2024
share grants |
2023
2019 – 2023
share grants |
| Risk-free rate |
7.49% |
7.97% |
| Expected volatility* |
30.83% |
36.88% |
| Expected dividend yield |
6.89% |
8.28% |
| Expected life (years) |
0.25 to 4.25 |
0.25 to 4.25 |
| Vesting periods (years) |
3 to 5 |
3 to 5 |
| Weighted average share price (Rand) |
R1.43 |
R1.27 |
| Weighted average exercise price (Rand) |
R1.58 |
R1.36 |
| Weighted average grant price (Rand) |
R0.3 to R1.85 |
R0.3 to R1.85 |
| Weighted average option value (Rand) |
R1.07 |
R0.86 |
| Performance conditions |
Yes |
Yes |
| Intrinsic value of shares |
R37.9 million |
R41.6 million |
| * |
The expected volatility of 30.83% (2023: 36.88%) is based on the historic volatility of the Merafe share price over the past five years. |
The following share grants relating to employees and executive directors were outstanding at 31 December 2024:
|
|
| |
| Vesting date |
Number of shares |
Share grant date |
| 1 April 2025 |
6 387 846 |
1 April 2020 |
| 1 April 2025 |
2 647 592 |
1 April 2021 |
| 1 April 2025 |
1 405 178 |
1 April 2022 |
| 1 April 2026 |
2 647 595 |
1 April 2021 |
| 1 April 2026 |
1 405 179 |
1 April 2022 |
| 1 April 2026 |
1 921 035 |
1 April 2023 |
| 1 April 2027 |
1 405 181 |
1 April 2022 |
| 1 April 2027 |
1 921 035 |
1 April 2023 |
| 1 April 2027 |
1 803 060 |
1 April 2024 |
| 1 April 2028 |
1 921 035 |
1 April 2023 |
| 1 April 2028 |
1 803 061 |
1 April 2024 |
| 1 April 2029 |
1 803 065 |
1 April 2024 |
|
| 27 070 862 |
|
The following share grants relating to executive directors were outstanding at 31 December 2024:
|
|
| |
| Vesting date |
Ms Z Matlala
Number of shares |
Mr D Chocho
Number of shares |
| 1 April 2025 |
3 904 904 |
1 685 363 |
| 1 April 2025 |
1 618 480 |
698 539 |
| 1 April 2025 |
709 641 |
324 299 |
| 1 April 2026 |
1 618 480 |
698 539 |
| 1 April 2026 |
709 641 |
324 299 |
| 1 April 2026 |
1 006 647 |
460 027 |
| 1 April 2027 |
709 641 |
324 299 |
| 1 April 2027 |
1 006 647 |
460 027 |
| 1 April 2027 |
910 671 |
461 946 |
| 1 April 2028 |
1 006 647 |
460 027 |
| 1 April 2028 |
910 671 |
461 946 |
| 1 April 2029 |
910 671 |
461 946 |
|
| 15 022 741 |
6 821 257 |
The movement in the number of share grants can be summarised as follows:
|
| 2024
Number of
shares |
2023
Number of
shares |
| Opening balance |
31 972 423 |
34 751 401 |
| Granted during the year |
5 409 186 |
5 763 105 |
| Vested during the year |
(9 673 090) |
(7 463 859) |
| Forfeited during the year |
(637 657) |
(1 078 224) |
| Closing balance |
27 070 862 |
31 972 423 |
|